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Abstract: Recently, it has been demonstrated that oxygen free radicals have an important 
role as a signaling messenger in the development of inflammation and osteoclastogenesis, 
suggesting the implication of oxygen free radicals in the pathogenesis of arthritis. The aim 
of this study was to examine the potential of a strong free-radical scavenger, water-soluble 
fullerene (C60), as a protective agent against synovitis in arthritis, both in vitro and in vivo. 
In the presence or absence of C60 (0.1, 1.0, 10.0 µM), human synovial fibroblasts, synovial 
infiltrating lymphocytes or macrophages were incubated with tumor necrosis factor-α (TNF-α) 
(10.0 ng/mL), and the production of proinflammatory cytokines by the individual cells were 
analyzed. C60 significantly suppressed the TNF-α-induced production of proinflammatory 
cytokines in synovial fibroblasts, synovial infiltrating lymphocytes and macrophages in vitro. 
Adjuvant induced arthritic rats were used as an animal model of arthritis. Rats were divided into 
two subgroups: control and treatment with C60 at 10.0 µM. The left ankle joint was injected 
intraarticularly with water-soluble C60 (20 µl) in the C60-treated group, while, as a control, 
the left ankle joint in the control rats received phosphate-buffered saline (20 µl), once weekly 
for eight weeks. Ankle joint tissues were prepared for histological analysis. In adjuvant-induced 
arthritic rats, intra-articular treatment with C60 in vivo reduced synovitis and alleviated bone 
resorption and destruction in the joints, while control ankle joints showed progression of syno-
vitis and joint destruction with time. These findings indicate that C60 is a potential therapeutic 
agent for inhibition of arthritis.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovitis 
involving synovial hyperplasia with neoangiogenesis and infiltration of lymphocytes 
and macrophages into the synovial tissue.1 Synovial infiltrating inflammatory cells, 
which produce various inflammatory cytokines and growth factors, are intimately 
involved in a variety of symptoms of RA.2 It is observed in the joint tissues of RA 
patients that the synovial hyperplasia erodes and destroys the bone and cartilage.1–3
In the management of RA, antitumor necrosis factor (anti-TNF-α) agents are 
becoming more widely available and offer the rapid onset of effective treatment, 
although there still remains no adequate explanation for some patients’ poor response 
to this class of agents.4–7 Even an excellent anti-RA drug cannot be effective for all 
patients; there are always responders and nonresponders to an individual antirheumatic 
drug.8,9 Furthermore, long-term administration of a drug induces tolerance, 
that is, reduction of drug effectiveness, to itself even in initial responders, who have International Journal of Nanomedicine 2009:4 218
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to increase its dosage or change drugs. Drug administration 
is also sometimes restricted due to a patient suffering 
complications.4–6 In order to treat nonresponders or patients 
who cannot take certain drugs because of complications, the 
development of a novel anti-RA drug is still much needed. 
Research into newer pharmacological therapies is ongoing 
with multiple compounds in development.10
Proinflammatory cytokines (TNF-α, interleukin-1 [IL-1], 
IL-6, IL-17, etc.) produced mainly by macrophages are inti-
mately involved in the pathogenesis of RA.1–3,10 It has already 
been demonstrated that reactive oxygen species (ROS) are 
increasingly produced by inflammatory cells in response to 
stimulation by proinflammatory cytokines such as TNF-α, 
IL-1, IL-6, and IL-17 and play an important role as a messenger 
of the intracellular signaling pathway (nuclear factor-kappaB 
[NFκB], P38, phosphatidylinositol-3 [PI3] kinase), suggesting 
that ROS in turn activates inflammatory cells that have a part 
in the progression of inflammation.11–17 These findings indicate 
that ROS has an important role in the generation of inflam-
mation. Targeting of ROS could have a therapeutic value as a 
strategy to reduce the development of inflammation.
In the joint of patients with RA, osteoclastic hyper-
resorption is accelerated as the disease progresses. The 
osteoimmunology, shared mechanisms, and crosstalk 
between the immune system and bone metabolism, are 
closely involved in the pathogenesis of RA.18–21 Induction 
of osteoclast differentiation from precursor cells is known 
to be linked by receptor activator of NFκB (RANK)–RANK 
ligand (RANKL) signals.20 RANKL is expressed by synovial 
fibroblasts, activated T cells and macrophages as well as 
osteoblasts and the expression is induced by proinflammatory 
cytokines including IL-1, IL-6, IL-17, and TNF-α, which are 
implicated in the pathogenesis of RA.20–22 These findings 
suggest that the bone metabolism is closely involved with 
the inflammation in a variety of diseases.
It has been already reported that several of the intracel-
lular signals essential for activation of inflammatory process, 
including NFκB, c-Jun amino-terminal kinase, PI3-kinase, 
and p38 MAPK, are sensitive to ROS.23–25 It has been dem-
onstrated that NFκB is a target for cellular activation by 
ROS,25,26 and that antioxidants suppress NFκB activation 
in osteoclasts.27–29 Recent studies clearly have revealed that 
ROS mediates the inflammation and immune response.25–28 
Thus, targeting of ROS could, therefore, have a distinct 
therapeutic value as a strategy to prevent the inflammation, 
such as synovitis, in arthritis.
Fullerene (C60) is composed of spherical carbon molecules 
with a unique cage structure.30,31 This compound has a high 
reactivity with oxygen free radicals and potential activity as 
a strong free radical scavenger.32 It has been reported that the 
antioxidant level of C60 is several hundred-fold higher than 
that of other antioxidants.32 Recently, C60 derivatives have 
shown some remarkable biologic properties such as neural 
apoptosis,33 promotion of chondrogenesis,34 and protection 
of skin keratinocytes from ROS-induced cell death after 
ultraviolet stress.35 We have already demonstrated that water-
soluble C60 fullerene, a strong free-radical scavenger, can 
function as a protective agent against catabolic stress-induced 
degeneration of articular cartilage in a model of osteoarthritis 
in vitro and in vivo.36 Water-soluble C60 significantly reduced 
articular cartilage degeneration in the osteoarthritis rabbit 
model. These findings suggest that C60 has the potential 
to protect against oxygen free radical-induced pathological 
features in a variety of diseases.37 Exploitation of C60 could 
lead to the development of novel therapeutic strategies in the 
prevention of both inflammation/synovitis and osteoclastic 
hyper-resorption in RA.
In the present study, we investigated the influence of 
water-soluble C60 on generation of inflammation in order 
to explore any therapeutic or protective effect of C60 on 
the synovitis in RA. We confirmed the suppressive effects 
of C60 on proinflammatory cytokine production from 
synovial inflammation-related cells. Our results indicated 
that intraarticular treatment with C60 significantly reduced 
synovitis and joint destruction in adjuvant-induced arthritic 
rats. These findings demonstrate that C60 has suppressive 
effects on synovitis and the resultant joint destruction in 
arthritis, suggesting that it could be useful for prevention 
and treatment of arthritis.
Patients and methods
cell culture
Synovial fibroblasts, synovial infiltrating lymphocytes and 
macrophages isolated from synovial tissue in patients with 
RA were used in this study. All samples were obtained after 
informed consent, and this study was approved by the local 
institutional ethics committee. Cell viability was determined 
by trypan blue exclusion.
Preparation of synovial fibroblasts
Fresh synovial samples were obtained at the time of arthro-
plastic knee surgery or knee joint synovectomy performed on 
eight female patients with RA (age range 50–78 years).
After careful removal of the adipose tissue, the synovial 
samples were cut into small pieces and minced, then incu-
bated in liquid low-glucose Dulbecco’s modified Eagle’s International Journal of Nanomedicine 2009:4 219
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medium (DMEM; Sigma, St. Louis, MO, USA) containing 
collagenase (Sigma) at 1.0 mg/ml at 37 °C overnight, after 
which the synovial fibroblasts were isolated for culture. 
After washing the cells with phosphate-buffered saline 
(PBS; Nissui Co., Tokyo, Japan), the cells were cultured 
in DMEM containing 10% heat-inactivated fetal calf 
serum (FCS; Wako Pure industries, Tokyo, Japan), 2 mM 
l-glutamine, 25 mM HEPES (2-[4-(2-hydroxyethyl)-1-
piperazinyl], and penicillin and streptomycin at 100 units/ml. 
The cells were incubated at 37 °C in a humidified atmosphere 
of 5% CO2 and 95% air. Cells were used from passage 2 to 5, 
during which time they were a homogeneous population 
of fibroblast-like synoviocytes.
Preparation of synovial infiltrating lymphocytes 
and macrophages
Fresh synovial samples were obtained as described above. 
After careful removal of the adipose tissue, synovial samples 
were minced on tissue culture plates, digested with collage-
nase (1 mg/ml) in RPMI-1640 (Gibco, New York, NY, USA) 
supplemented with 10% FCS, incubated for six hours at 37 °C, 
filtered through a 70-µm nylon mesh, and centrifuged. The cell 
pellet was resuspended in RPMI-1640/10% FCS at a density 
of 1 × 106 cells/ml, and seeded onto culture plates. After a six-
hour incubation, nonadherent cells were harvested, and were 
used to isolate lymphocytes by Ficoll-Paque density gradient 
centrifugation. Adherent cells were harvested and enriched 
CD68 monocytes were purified by magnetic depletion of 
non-CD68 positive cells, using the MACS indirect magnetic 
labeling system according to the manufacturer’s instructions 
(MACS; Miltenyi Biotec, Auburn, CA, USA). The cells were 
cultured in RPMI 1640 with 10% FCS at 37 °C in a humidified 
atmosphere of 5% CO2 and 95% air.
Effect of C60 on production of proinflammatory 
cytokines by synovial fibroblasts, infiltrating 
lymphocytes and macrophages
Arthritis is an inflammatory disease where inflammation 
occurs mainly in the synovium of the joint. We studied the 
direct action of C60 on synovial infiltrating lymphocytes 
and macrophages as well as synovial fibroblasts from the 
perspective of production of proinflammatory cytokines by 
these cells. Water-soluble C60 was purchased from Vitamin 
C60 Bio Research (Tokyo, Japan).38,39
To examine the effect of C60 on the production of 
cytokines by synovial fibroblasts, synovial infiltrating lym-
phocytes and macrophages, the levels of proinflammatory 
cytokines produced by individual cells were analyzed by an 
enzyme-linked immunosorbent assay (ELISA) and Western 
blot analysis. A single cell suspension was seeded on 24-well 
culture plates at 5 × 105 cells/well. The cells were incubated 
with C60 in the presence or absence of TNF-α (10.0 ng /ml) at 
37 °C in a humidified atmosphere of 5% CO2 and 95% air. The 
concentration of C60 was 0.1, 1.0, or 10.0 µM. After a 24-hour 
incubation, the culture medium and cells were collected 
for ELISA and Western blot analysis, respectively.
The levels of proinflammatory cytokines, TNF-α and IL-1β 
in cell cultures were measured using an ELISA kit (ELISAs 
for TNF-α from Amersham Biosciences, Buckinghamshire, 
UK; IL-1β from R&D Systems, Minneapolis, MN, USA) in 
accordance with the manufacturer’s protocol. Data from four 
independent experiments were analyzed.
Efficacy of C60 in animal models 
of arthritis
We investigated whether C60 had any suppressive effects on 
arthritis (synovitis and joint destruction) using a rat arthritis 
model. Eight-week-old female Sprague–Dawley rats were 
obtained from Charles River Laboratories Japan (Tokyo, 
Japan). Adjuvant-induced arthritic rats were created as 
described in a previous report.40 To illustrate the pathology 
of RA, many models have been made to mimic the human 
RA process, among which adjuvant-induced arthritis model 
was most widely used. Indeed, the adjuvant-induced arthritis 
model has many morphological features similar to those 
of human RA, including patterns of synovitis, synovial 
hyperplasia, neoangiogenesis and infiltration of inflammatory 
cells into the synovial tissue, pannus formation, and erosion 
of the articular cartilage and bone. Moreover, the arthritis 
model shares many of the cytokines and biological factors 
in the synovium and cartilage with RA.
The ankle joints of 40 rats were assessed. After being 
once immunized to produce arthritis, the rats were divided 
into a control group (n = 20 rats) and a C60-treated group 
(n = 20 rats). In the control group, the left ankle joint was 
treated with an intraarticular injection of 20.0 µl PBS once 
per week for eight weeks, using a micro-needle syringe. In the 
C60-treated group, the left ankle joint was similarly treated 
with an intraarticular injection of 20.0 µl C60 (10.0 µM) 
once per week for eight weeks. The right knee joints were 
not treated in either group to be compared to the contralateral 
ankle joints for the observation of arthritis development and 
progress.
The levels of arthritis of the left ankle joints were evalu-
ated according to the arthritis score41 every two weeks after 
immunization. After observation to assess the arthritis International Journal of Nanomedicine 2009:4 220
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Figure 1 effects of c60 on the production of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) in synovial fibroblasts, synovial infiltrating lymphocytes and macrophages. 
Synovial fibroblasts, synovial infiltrating lymphocytes or macrophages were incubated with catabolic factor, TNF-α (10.0 ng /ml) in the presence or absence of water-soluble 
c60 (0.1, 1.0, or 10.0 µM).   After 24-hour incubation, the concentrations of proinflammatory cytokines were analyzed by ELISA (A: TNF-α, B: IL-1β).   TNF-α stimulated the 
production of TNF-α and IL-1β by individual cells (*P  0.05, **P  0.01 compared to each control). C60 significantly decreased the TNF-α-induced excess production of 
TNF-α A) and IL-1β B) from individual cells (*P  0.05, **P  0.01). Data from four independent experiments were analyzed.International Journal of Nanomedicine 2009:4 221
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score, the rats were euthanized one, two, four, six, and eight 
weeks (four rats per time point) after immunization and 
both ankle joints were harvested. Bone and cartilage tissue 
blocks were prepared for histological analysis. All experi-
ments were conducted with the approval of the University 
Animal Care and Use Committee.
Articular bone and cartilage samples were fixed for two 
days in 4% paraformaldehyde solution and then decalcified 
in 4% paraformaldehyde containing 0.85% sodium chloride 
and 10% acetic acid. Tissues were dehydrated through a series 
of ethanol solutions and infiltrated with xylene before being 
embedded in paraffin and cut into 6-µm sections. Sections 
were deparaffinized through sequential immersion in xylene 
and a graded series of ethanol solutions in accordance with 
conventional procedures. The pathological tissue scores were 
calculated to histologically assess arthritis stages.40–42 The 
mean damage score from the six samples from each animal 
was used to determine the mean ± standard deviations for 
each group. Three independent observers assessed cartilage 
damage in a blinded manner.
statistical analysis
Results are expressed as means ± standard deviations. 
Data were analyzed by a nonparametric statistical analysis. 
A P value  0.05 was considered statistically significant.
Student’s t-test was used to assess the differences between 
C60-treated and control groups with respect to arthritis and 
histological parameters. When a statistically significant 
difference between the two groups was detected, analysis of 
variance (ANOVA) was used to adjust for the confounding 
effects of animals and observers.
Results and discussion
c60 decreases the production 
of proinflammatory cytokines in synovial 
inflammation-related cells
TNF-α significantly stimulated the production of TNF-α 
(Figure 1A) and IL-1β (Figure 1B) by synovial fibroblasts, 
synovial infiltrating lymphocytes and infiltrating macrophages. 
In synovial fibroblasts, treatment with C60 (10.0 µM) 
significantly inhibited the TNF-α-induced excess produc-
tion of TNF-α and IL-1β by the cells in synovial infiltrating 
lymphocytes and macrophages, C60 at 1.0 or 10.0 µM 
significantly suppressed the accelerated production of both 
proinflammatory cytokines, TNF-α and IL-1β, under catabolic 
stress, due to  TNF-α at 10.0 ng /ml (Figures 1A, B). Our 
in vitro studies indicate that water-soluble C60 inhibits the 
following arthritis-related responses: the production of the 
proinflammatory cytokines, TNF-α and IL-1β from synovial 
fibroblasts, synovial infiltrating lymphocytes and macrophages. 
The results of our in vitro experiments suggest that C60 could 
have the potential to inhibit inflammatory synovitis in RA. 
The inhibitory effect of C60 on inflammation is based on 
the evidence that ROS is closely involved in the activation 
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Figure 2 Intraarticular treatment of c60 inhibits the arthritis score in the arthritis 
model rats. In each rat after immunization, the left ankle joint was treated by intra-
articular injection of the appropriate solution (20.0 µl, control: phosphate-buffered 
saline, c60-treated group: 10.0 µM c60) by micro-needle syringe once a week dur-
ing the observation periods. In the control joint group, the arthritis score gradually 
increased with the advance of time.   The score in the left ankles of rats that had been 
treated with c60 (10.0 µM) showed lower at four and eight weeks after immunization 
in contrast to the control ankle joints (four rats per time point).
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Figure 3 Intraarticular treatment of c60 inhibits the pathological score in the arthritis 
model rats. The degree of arthritis was histologically evaluated in each ankle joint 
sample (four rats per time point).   Although infiltration of inflammatory cells into the 
synovium and joint destruction progressed with time in both control and c60-treated 
groups, the C60-treated group showed significantly lower pathological tissue scores 
at four weeks and later compared to the respective control group.International Journal of Nanomedicine 2009:4 222
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Figure 4 Representative images of the joint damage at each time point in arthritis model rats. A) After four weeks of treatment, there was a tendency in the group treated 
with phosphate-buffered saline (PBs) towards a more severe degree of synovitis than in the group treated with c60 (10.0 µM). B) At six weeks after immunization, intraarticular 
treatment with C60 inhibited the infiltration of inflammatory cells, synovial hyperplasia, and bone resorption by multinucleated osteoclastic cells in the ankle joints of arthritis 
model rats, whereas the control joints that was treated with PBs showed more severe damage. C) At the eight-week time point, all ankle joints that had been treated with PBs 
showed severe joint destruction and bony ankylosis. In contrast, inhibitory effects were observed following administration of c60 in the c60-treated group.
of inflammation-related cells. ROS is a messenger of the 
intracellular signal pathway for generation of inflammation.11–17 
These results suggest that C60 might be used as an agent for 
suppressing proinflammatory cytokine production by infil-
trating cells in RA synovial tissue and the resultant bone and 
joint destruction. It was suggested that C60 might be effective 
in the therapy and prevention of arthritis such as RA through 
suppression of inflammation by the cells involved.
Arthritis score in the arthritic rat model
Indeed, we have found that C60 significantly reduced the 
synovitis, such as synovial hyperplasia and infiltration of 
inflammation-related cells, and bone resorption/destruction in 
the adjuvant-induced arthritic rat model, suggesting that this 
compound has protective properties against the arthritis.
The levels of arthritis of the ankle joints were analyzed 
according to the arthritis score. The control group had swollen 
and reddened ankle joints which were aggravated with time. 
In contrast, the C60-treated group showed significantly lower 
arthritis scores at the four-week time point and at the eight-
week time point compared to the control group (Figure 2). 
The mean scores at the six-week time point were lower in 
the C60 than in the control groups, although no significant 
difference was observed between the two groups.
Pathological tissue score in the arthritic 
rat model
Adjuvant-induced arthritic rats were administered C60 
(10.0 µM) once per week by intra-articular injection into 
the ankle joints during the development of arthritis. The 
severity of arthritis was monitored every two weeks after 
immunization. Concerning pathological tissue scores, the 
results were consistent with the arthritis scores. Although 
infiltration of inflammation-related cells into the synovium International Journal of Nanomedicine 2009:4 224
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and joint destruction progressed with time in both control and 
C60-treated groups, the C60-treated group showed signifi-
cantly lower pathological tissue scores at four weeks and later 
as compared to the respective control group (Figure 3).
In the control joints, at the four-week, six-week, and 
eight-week time points, histological features of arthritis 
were evident. These joints exhibited cartilage degeneration 
(extension of the area of surface fibrillation, chondrocyte 
clustering, abnormal deposition of chondrocytes and a 
decreased cell density with cartilage thinning), syno-
vial hyperplasia with neoangiogenesis, infiltration of 
inflammation-related cells into the synovial tissue, and 
bone resorption/destruction by multinucleated osteoclastic 
cells of the subchondral bone and areas of exposed bone. 
As time progressed, the joints in rats that had received an 
intra-articular injection of PBS showed progressive joint 
destruction and synovitis (Figures 3, 4). Eight weeks after 
immunization, all joints showed marked joint destruction 
and ankylosis (Figure 4C).
In contrast, as shown in the representative images in 
Figures 4A–C, treatment of the ankle joints with C60 
markedly inhibited synovitis, such as synovial hyperplasia 
and infiltration of inflammation-related cells, and joint 
destruction in the adjuvant-induced arthritic rats. After four 
weeks of treatment, there was a tendency in the group treated 
with PBS towards a more severe degree of synovitis than in 
the group treated with C60 (Figures 3, 4A). In particular, 
after the eight-week time point, all ankle joints that had 
been treated with PBS showed severe joint destruction and 
bony ankylosis. In contrast, more mild damage was observed 
following administration of C60 (Figure 4C).
In the present study, we have evaluated the safety and 
toxicity of C60 fullerene through the monitor of body weight 
and hair/skin condition of animal model rats. During the 
study period, no significant differences in the body weight 
and hair condition were observed between the control group 
and the C60 treated rats group. Also, we have histologically 
confirmed the organs in the C60 treated rats at eight weeks 
after surgery. The treatment with water-soluble C60 did not 
result in acute and subacute toxicity in organs such as brain, 
lung, liver, kidney, testis, and adrenal gland, which were 
obtained from all C60-treated rats (data not shown). In these 
organs, tissue necrosis, fibrosis, and other degenerative signs 
were not observed. In addition, no significant differences 
were observed in the serum levels of alanine aminotransferase 
activity during the study period in the C60-treated rats, 
suggesting that C60 did not incur any acute or subacute liver 
dysfunction in the rabbits (data not shown).
In our previous study, the effect of C60 on degeneration 
of articular cartilage was compared with that of sodium 
hyaluronate, which has lubricating, coating and joint 
protecting functions, in the OA rabbit model.38 The result 
showed that the inhibitory effect of C60 on cartilage 
degeneration was superior to that of sodium hyaluronate. 
In addition, combined treatment of C60 and hyaluronic 
acid showed a significant reduce of cartilage degeneration 
in comparison with that with C60 or sodium hyaluronic acid 
only, suggesting the therapeutic value of C60 fullerene in 
comparison with known agent and the potential usefulness 
of combined therapy of C60 with known agents. In the 
next study, we plan to compare the inhibitory effect of C60 
fullerene with corticosteroid and/or other agents in the 
adjuvand arthritis rat model.
In conclusion, our findings indicate that water-soluble 
C60 fullerene can function as a protective agent against 
proinflammatory cytokine production from synovial 
inflammation-related cells and the resultant synovitis in vitro. 
Intra-articular treatment with this compound significantly 
reduces synovitis and joint destruction in the rat model of 
arthritis. These findings suggest that C60 fullerene may be 
useful as a therapeutic agent for arthritis.
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